BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. 1989

M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Istituto Nazionale per la Ricerca sul Cancro, Servizio di Oncologia Medica, Genova.

A pilot study was undertaken to evaluate toxicity and activity of recombinant alpha-2b interferon in patients with metastatic malignant melanoma. Interferon was administered at the dosage of 10 x 10(6) IU/m2, 3 times a week i.m. 21 patients entered the study, 17 pretreated with chemotherapy and/or immunotherapy and 6 untreated. We obtained 3 partial responses (14.3%; 95% CL, 3.0-36.3%); 9 patients had stable disease. All patients experienced flue-like symptoms and fever; most fatigue and worsening of performance status. Recombinant interferon alpha-2b at the dosage and schedule used has limited but definite activity in metastatic malignant melanoma; the substantial subjective toxicity must be taken into consideration. Further trials testing recombinant alpha interferon in combination with chemotherapeutic agents, like DTIC, are warranted.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500

Related Publications

M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
A phase II trial of recombinant interferon alpha-2b and cisplatin in metastatic melanoma.
January 2000, Acta oncologica (Stockholm, Sweden),
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
July 1986, Cancer,
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma.
August 1998, American journal of clinical oncology,
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
June 2006, Cancer,
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
August 1988, Journal of biological response modifiers,
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Treatment of metastatic malignant melanoma with recombinant interferon alfa-2b.
January 1987, Investigational new drugs,
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
January 2011, Journal of immunotherapy (Hagerstown, Md. : 1997),
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma.
February 1988, American journal of clinical oncology,
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
January 1992, European journal of cancer (Oxford, England : 1990),
M R Sertoli, and M G Bernengo, and A Ardizzoni, and I Brunetti, and A Falcone, and M G Vidili, and M P Cusimano, and A Appino, and G Doveil, and C Fortini
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
August 2006, Melanoma research,
Copied contents to your clipboard!